ArticleFrontiers in pediatrics2026
Case Report: Effective use of rituximab in children with steroid-resistant/dependent idiopathic pulmonary hemosiderosis: description of two cases and literature review.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Idiopathic pulmonary hemosiderosis (IPH) is a rare, chronic, and potentially life-threatening disorder predominantly affecting the pediatric population. While most patients respond to conventional immunosuppressive therapy, management of steroid-resistant/dependent cases remains challenging. This study aims to evaluate the efficacy and safety of rituximab (RTX) in the treatment of steroid-resistant/dependent IPH in children. Methods: We report two pediatric cases of steroid-resistant/dependent IPH who were admitted to our institution. Both patients presented with severe, recurrent diffuse pulmonary hemorrhage and demonstrated poor response to conventional therapy including high-dose corticosteroid pulse therapy and combination immunosuppressants. Clinical data, laboratory findings, radiographic features, treatment regimens, and outcomes were collected and analyzed. Results: Both patients exhibited steroid resistance or dependence with persistent or recurrent pulmonary hemorrhage despite aggressive conventional immunosuppression. Following RTX administration, rapid and sustained hemorrhage control was achieved in both cases. Clinical remission was maintained over follow-up periods of 6 months for both patients, with successful corticosteroid tapering and no significant infusion-related adverse events observed. No disease relapse occurred during the follow-up period. Conclusion: Rituximab appears to be an effective and well-tolerated rescue therapy for steroid-resistant/dependent IPH in children, offering sustained hemorrhage control and facilitating corticosteroid-sparing. Given the limited existing literature on RTX application in IPH management, this report offers a novel therapeutic approach for steroid-resistant/dependent IPH cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.